|
David Dodds has lead interdisciplinary process
development groups using biological methods to perform organic synthesis for
over 25 years. Most recently,
David established Dodds & Associates, providing technical management and
diligence to start-up pharma, biotech, and industrial biotech companies,
primarily focusing on the use of biological methods to produce non-fuel
chemicals. Prior to Dodds and
Associates, he was Director of Fermentation and Biocatalysis Development at
Bristol-Meyrs Squibb. He led chemical process development, molecular biology,
industrial fermentation, and GMP analytical services, supporting both Discovery
and Production. Before BMS, David established a new group within Chemical
Process Development at Schering-Plough. His group introduced biocatalysis in
over a dozen projects at scales ranging from lab-bench scale synthesis of drug
metabolites, to GMP pilot-plant batches providing intermediates for clinical
compounds, two of which were approved. Under David's leadership, the
group filed 13 patent disclosures and produced a total of 37 public
presentations and publications. David
obtained his Ph.D. in synthetic organic chemistry from the University of
Toronto.
|